Published: 3 December 2020


MARC’s remarks: September 2020 meeting

Published: 3 December 2020
Prescriber Update 41(4): 65

December 2020

The Medicines Adverse Reactions Committee (MARC) gathered through videoconference on 10 September 2020 to discuss a number of medicine-related safety issues.

The MARC discussed a very rare adverse reaction reported to the Centre for Adverse Reactions Monitoring (CARM ID: 136929), where a patient used ocular chloramphenicol and died months later from aplastic anaemia. The MARC recommended highlighting this case in Prescriber Update (see the Gathering Knowledge article).

The MARC discussed the potential risks of macrolide antibiotic use in pregnancy but considered no action was needed at this time due to limited and inconsistent evidence.

The MARC reviewed the benefits and risks of domperidone use in children aged under 12 years. As the evidence from the scientific literature and a post-market study showed lack of efficacy for domperidone use in this age group. The MARC recommended that the data sheet indication be revised to specify the use of domperidone in adults and children aged 12 years and older.

See the Medsafe website for the MARC meeting minutes and the reports presented to the MARC.

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /